

# Curriculum Vitae Marten Smidt

June 4, 2021

## Contents

<b>1</b>	<b>Personal details</b>	<b>2</b>
<b>2</b>	<b>Education</b>	<b>2</b>
<b>3</b>	<b>Civil service</b>	<b>2</b>
<b>4</b>	<b>Professional experience</b>	<b>2</b>
<b>5</b>	<b>Professional activities</b>	<b>3</b>
5.1	Grant support . . . . .	3
5.2	Reviewing/editorial activities . . . . .	4
5.3	Brief summary of research . . . . .	4
5.4	Trainees . . . . .	6
5.4.1	PhD students: . . . . .	6
5.4.2	Promoter: . . . . .	7
5.4.3	Master Students: . . . . .	7
5.4.4	Other trainees . . . . .	8
5.5	Selection of invited lectures . . . . .	8
5.6	Selection of current and past collaborations with (foreign) academic groups . . . . .	10
5.7	Selection of management activities . . . . .	11
5.7.1	Research management . . . . .	11
5.7.2	IT management . . . . .	11
5.7.3	Managment trainings/activities . . . . .	12
5.7.4	Personal management . . . . .	12
<b>6</b>	<b>Business development</b>	<b>12</b>
<b>7</b>	<b>Educational experience</b>	<b>12</b>
<b>8</b>	<b>Selected honors</b>	<b>13</b>
<b>9</b>	<b>List of publications, books and patent applications</b>	<b>13</b>
9.1	Pre-print published manuscripts . . . . .	13
9.2	Peer refereed international journals (impact factors (IF) are listed) . . . . .	14
9.3	Patent applications: . . . . .	20
9.4	Companies . . . . .	20
9.5	Books (chapters) . . . . .	20
9.6	Other scientific contributions . . . . .	20
<b>10</b>	<b>Citation information</b>	<b>21</b>

## 1 Personal details

Name Marten Piet Smidt, PhD

Birth-date March 18, 1965

Affiliation University of Amsterdam, Swammerdam Institute for Life Sciences P.O. Box 94215 | 1090 GE Amsterdam  
Sciencepark 904 | Room C4.102 | 1098 XH Amsterdam

Telephone: +31 20 525 6479

Fax: +31 20 525 7934

Email: m.p.smidt@uva.nl

Website: <http://www.martensmidtlab.eu>; [www.macrobianbiotech.com](http://www.macrobianbiotech.com)

## 2 Education

- Higher Laboratory Education: September 1981-August, 1984, Main subject :Medical Microbiology
- Biology, University of Groningen: September 1986- March 1991, Main Subject :Biochemistry/Microbial-Physiology
- Doctorate at University of Groningen: June 1991- May 1996, Title of thesis :Two DNA-binding proteins recognizing the apo-VLDL-II gene cis-regulatory element D.
- BKO (2012) degree for education
- SKO (2016) degree for advanced education skills

## 3 Civil service

- 1984-1986: Staff member in the division hospital in the Seedorf Facility, Germany

## 4 Professional experience

- 1986: Technician at the special blood bank facility as part of "Eurotransplant", Academic Hospital Groningen, The Netherlands
- 1991-1995: PhD in the group of Dr. Geert AB: Analysis of the involvement of liver specific or enriched transcription factors on the liver specific and estradiol inducible apoVLDL II gene, University of Groningen, The Netherlands.
- 1995-1999: Postdoc at the Rudolf Magnus Institute for Neuroscience in the lab of Prof Dr. J.P.H. Burbach: Study of brain development in relation to mental disorders and cloning of specific transcription factors which are involved in that process, University of Utrecht, The Netherlands.
- 2000- 2006: Assistant professor at the Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands.
- 2001-2011: Team leader of the midbrain dopaminergic system research team at the Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands.
- 2002-2011: Coordinator Section Developmental Neuroscience of the Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands
- 2006-2009: Associate professor in the department Neuroscience and Pharmacology, University Medical Center, Utrecht, The Netherlands.
- 2008-2011: Head of the research platform Neurodevelopment, department Neuroscience and Pharmacology, University Medical Center, Utrecht, The Netherlands.
- 2009-2011; Full Professor, chair: Developmental Neurobiology, department Neuroscience and Pharmacology, University Medical Center, Utrecht, The Netherlands.
- 2011-present: Full Professor, Molecular Neuroscience, Center for Neuroscience, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands

- 2015-2021: Director of the Swammerdam Institute for Life Sciences (SILS), University of Amsterdam, Amsterdam, The Netherlands.
- 2017-present: Founder/CEO of a drug development company: Macrobian Biotech BV with co-founder dr. L.P. van der Heide, Amsterdam, The Netherlands.

## 5 Professional activities

### 5.1 Grant support

1. 1998-2001: National Parkinson Foundation Research Grant: Involvement of the homeobox gene Pitx3 in development and maintenance of mesDA neurons. (PI)
2. 1999-2001: NWO-MW Fellowship: The role of the novel homeodomain Pitx3 in molecular cascades of development and maintenance of the mesencephalic dopaminergic system. (PI)
3. 1999-2002: Korczak Foundation Fellowship: Molecular processes in brain development, Postdoc 3 years. (PI) (With co-PI JPH burbach)
4. 2000-2004: Korczak Foundation Project: Molecular processes in brain development, PhD 4 years, (PI) (With co-PI JPH burbach)
5. 1999-2001: Industrial project with Solvay Pharmaceuticals: Pitx3 function and development of model systems with disturbed mesencephalic dopamine systems . Postdoc (PI) (With co-PI JPH burbach)
6. 2000-2002: NWO-MW grant: Genetic and epigenetic control of mesencephalic dopamine system development, Framework of scientific cooperation between The Netherlands and the Russian Federation. (PI with co-PI WH Gispen )
7. 2003-2007: NWO-ALW grant: The Pitx3 homeobox gene cascade and dysfunction of the midbrain dopamine system. (PI) (with co-PI JPH burbach)
8. 2004-2009: Hypotential program of the University of Utrecht: BAMI: Brain Analysis through Molecular Imaging (PI) (With co-PI Freek Beekman)
9. 2004: Brain Foundation in The Netherlands (Hersenstichting Nederland) research grant. (PI)
10. 2006-2010: NWO-ALW research grant: Identification of Pitx3 regulated genes in midbrain dopamine neurons (PI)
11. 2007-2011: TI-Farma initiative, The Netherlands: 2 PhD and 1 PD position (PI with co PI J Pasterkamp and JPH Burbach))
12. 2007: Brain Foundation in The Netherlands (Hersenstichting Nederland) research grant. (PI)
13. 2009-2012: FP7 EU-grant proposal/project, medium sized EU-research project (coordinator and PI)
14. 2009-2014: NWO-ALW VICI grant (PI)
15. 2009-2013: NWO-ALW program grant (PI)
16. 1009: ZonMw (NWO) ZonMw-networkgrant (for FP-7 meeting).
17. 2012-2013: 4\* publication grants (NWO) open acces publications.
18. MRA-cluster grant “Impact” 2013-2015. (co-PI with “Innoser” (company)).
19. 2015-2017: Host to the Marie Curie fellowship of Dr. F. Jacobs (2015-2017).
20. 2016-2020: Research grant from the dutch Parkinson Foundation (PI: Dr. J.P. van de Heide).
21. 2017: Research grant from the “Dorpman-Wigmans Stichting” (with co-PI Lars vd Heide, 58kEuro equipment).
22. 2017: Proof of concept grant (PI; 100kEuro)
23. 2017: Valorisation grant from FNWI-UvA for the spin-off company Macrobian-Biotech (PI, founder; 230 kEuro).
24. 2017: Matching funds from UvA holding for the spin-off company Macrobian-Biotech (PI, founder; 500 kEuro).
25. 2017: NWO-TTW, Take off Phase 1, Towards the identification of a novel compound to treat Parkinson’s disease (PI, 40 kEuro).

26. 2019: Proof of concept grant (PI; 200kEuro).
27. 2020: Proof of concept grant (PI; 300 kEuro (milestone based 100 kEuro each year for 3 years)).
28. 2020: Pitt Hopkins UK research grant (PI; 70 kEuro)
29. 2020: Pitt Hopkins NL research grant (PI; 20 kEuro)
30. 2020: Zeldzame ziekten fonds (PI, 52 kEuro toegezegd in werving activiteiten door het fonds)
31. 2021: Research grant from the dutch Parkinson Foundation (250 kEuro, coPI with main PI: Dr. L.P. van der Heide).

## 5.2 Reviewing/editorial activities

- Reviewer for Science, Trend in Cell Science, Journal of Neurochemistry, Neuroscience, European Journal of Neuroscience, European Journal of Pharmacology, Journal of Biochemistry, Gene, Pharmacology Biochemistry and Behavior, Cell, Trends in Pharmacological sciences, PNAS, Frontier journals and Development.
- Grant reviewer for the Netherlands and Israel organizations for scientific research.
- Member of the grant evaluation board of NWO-ALW(2005-2009).
- Member of the NWO-ALW-VENI committee (2007-2010).
- Member of the NWO-Life Sciences domein panel (2009 and 2010).
- Member of the expert committee for the 2010 Marie Curie Individual fellowships evaluation LIFE Panel. EU, Brussels (2010, 2011).
- French National Research Agency (ANR) reviewing.
- Member of the Reviewing board of Frontiers in Neuroanatomy (2008-current).
- Editorial Board Member of Stem Cell Review Letters (2009-present).
- Member of the NWO-domain (ALW/ENW)grant evaluation board (2009-2017).
- French National Research Agency (ANR) non-thematic programme reviewing (Neuroscience, 2010-current).
- Editorial Board member of ISRN Developmental Biology (2012-current).
- EU Marie Curie program Evaluation (2010-current).
- Member of the NWO-ALW-VIDI board (2011-2014 (chair)).
- Member of the VICI grant evaluation board of NWO (2018-current).
- Referee for Donders Institute PhD project competition (2018).

## 5.3 Brief summary of research

My main interest is molecular programming during development of the central nervous system. Since at that time almost nothing was known on the subject, I started on a cloning effort to identify transcription factors that play a role during CNS development. From this work three major breakthroughs were established:

1. The cloning, identification and characterization of the homeobox gene Pitx3 (publication 105). This gene was found to be exclusively expressed in the substantia nigra (SNc) and ventral tegmental area (VTA) forming the midbrain dopamine system, essential for mood and movement regulation in mammals. The real impact of the work was that this factor is exclusively expressed in these neurons and this formed the first step in the understanding of molecular programming of midbrain dopamine neurons.
2. The identification of the role of the orphan nuclear hormone receptor Nurr1 (publication 104). It was shown by us and others that Nurr1 is essential for the development of fully differentiated midbrain dopamine neurons. This was the second factor identified to be involved in midbrain dopamine neurodevelopment.
3. The identification of Lmx1b (publication 101). We showed that the early specification of the midbrain by Lmx1b is essential for the formation of midbrain dopaminergic neurons. Moreover, we showed that TH expression was possible in early DA neurons without the expression of Pitx3, indicating that Pitx3 might be involved in molecular processes other than transmitter phenotype.

After this cloning and descriptive phase I was interested to go into depth into the role of Pitx3 (as an NWO fellow) in the neurodevelopment of midbrain dopamine neurons and to broaden my view on molecular signaling events in neuronal cells. This was accomplished by the start of analysis of the Pitx3 knock out and by the start of a new research line on forkhead proteins (FoxO). The work lead to two major findings:

1. The data from the Pitx3 knock-out analysis (aphakia mouse) formed a new chapter in the understanding of the role of Pitx3 in the development of midbrain dopamine neurons (publication 88). We showed that Pitx3 is essential for the formation of the SNc and the ventral part of the VTA. Moreover it was clear from the analysis that the defect was apparent at the early stage of terminal differentiation, Most importantly, the defect was not present in all midbrain dopamine neurons but mainly in the ventral medial SNc and ventral VTA.
2. The cloning and functional characterization of FoxO6, a novel member of the FoxO family (FoxO1, FoxO3 and FoxO4). We showed that FoxO6 had unique properties in terms of nucleo-cytoplasmic shuttling, as a result of PKB signaling, compared to its family members (publication 94). Later we showed the mechanism of the altered shuttling behavior and showed that phosphorylation by PKB does inactivate FoxO6 by inhibiting DNA interaction without the extra level of inhibition of nuclear removal (publication 81). We have gained quickly a good position by this work. A review from our team received much enthusiasm as highlighted by 82 citations so-far and the 25th place of most downloaded papers in the publication year (publication 87).

The fact that a subset of the complete group of dopamine neurons was affected in the Pitx3 knock-out (Pitx3 itself is expressed in all midbrain dopamine cells) initiated the novel idea that the molecular coding of the SNc and VTA is not the same. A real step forward was made by the identification of subset specific markers and coding differences in the ventricular zone. This concept of subset specification was a crucial step in the way the field regarded the molecular pathways leading to the development of dopamine neurons of the SNc and VTA (publication 72). In addition, it became clear that the neurons populating the SNc and VTA are not generated exclusively in the midbrain but also in the diencephalon. Therefore, the name of this neuronal group was changed to mesodiencephalic dopaminergic (mdDA) neurons and has been used as such from that point on.

This was a crucial moment in my career, i established my own group and my work clearly surpassed the initial identification and function-description of transcription factors involved in the development of mdDA neurons. My interest went into two additionally research directions:

1. The live visualization of dopamine neurotransmission through multi-pinhole SPECT. Prof dr. Freek Beekman designed a spectacular micro-SPECT system to follow tracers in the mouse brain with a resolution of 0.3 mm. Together we started to image live dopamine transmitter events in a living mouse. This work has lead to two high impact publications (publication: 80 and 59).
2. Understand how subset specification is established, which subsets exist and what the relationship is between subset and specific connectivity. A crucial finding in the understanding of subsets specific molecular coding was established through the identification of a subset specific transcriptional target of Pitx3. This gene, (retinal) aldehyde dehydrogenase 2 (Ahd2, Raldh1) is expressed, in the adult brain, in the ventral cells of the SNc and VTA, the neurons that are lost in the Pitx3 mutant (publication 61). A second novel finding was that retinoic acid (RA) has a role in terminal differentiation of this specific set of neurons in addition to its role in the ventricular zone. Ahd2 is present in ventricular zone cells, its transcription is terminated when cells leave the ventricular zone and under the control of Pitx3, Ahd2 is transcribed again in a (lateral) subset of mdDA neurons and is essential for the synthesis of RA out of retinal. We were able to show the dependence of mdDA differentiation for RA signalling by rescuing the Pitx3 knock-out phenotype through the exogenous application of RA.

Although I am still working on- and interested in the FoxO6 knock out (we have generated ko animals) my main interest lies with the molecular programming of mdDA neuronal subsets. My lab is currently investigating 1) why Ahd2 activation is only happening in the described subset; 2) we are mapping transcriptional targets of Engrailed, Lmx1a/b, and Nurr1 to get a better idea about the molecular programming that is initiated within mdDA neurons; 3) the functional interaction between Pitx3/Nurr1 (publication 56) and En1 and 4) we are finalizing the identification of adult subset specific markers. At that moment my research group consist of 4 PhD students, 3 postdocs, 2 technicians, one eu-program manager and every year about 3 master students.

The work described above has been very fruit-full and has lead to a leading position of my research group mainly in the field of development and engineering of mdDA neurons, marked by many invitations to write reviews/books on the topic, the high amount/level of peer-reviewed publications and the invitations to speak at the international level about my work.

In the summer of 2011, i decided to move the work-group to the Swammerdam Institute for Life Sciences at the University of Amsterdam and started the "Molecular Neuroscience" section. I have new opportunities to build further on the scientific output and have more funding/equipment available to perform cutting edge work in the direction of molecular programming of neuronal systems.

The molecular Neuroscience team has expanded and the following research lines are now active: Molecular mechanisms in midbrain development: Prof. Dr. M.P. Smidt; Signal transduction in the developing and adult midbrain: Prof.

Dr. M.P. Smidt and Dr. L.P. van der Heide; Insulin signaling and circadian rhythms in the developing and adult brain: Prof. Dr. M.P. Smidt and Dr. M.F.M. Hoekman; Functional development of cortical microcircuits: Dr. J.A. van Hooft (until 2017); Primate Genome Evolution and Human Brain Development: Dr. F.M.J. Jacobs. Our scientific endeavors have precipitated in the UvA education program where we developed a education-line towards molecular neuroscience and generated a master program of the same name.

Next to these activities I have been appointed Director (2015) of the Swammerdam Institute for Life Sciences (SILS; 250 fte) of the University of Amsterdam.

In 2017 I have founded a biotechnology company: Macrobian Biotech BV ([www.macrobian-biotech.com](http://www.macrobian-biotech.com)), together with co-founder Dr. Lars van der Heide and supported by UvA ventures BV. Within this UvA-spin-off we develop novel medication towards the modulation of dopaminergic function, as for example for the treatment of Parkinson's disease. Macrobian Biotech is a pre-clinical drug development company aimed to produce proof-of-concept and runs until stage 1-2 of clinical trials.

## 5.4 Trainees

### 5.4.1 PhD students:

1. 1997-2001: Cerial Asbreuk: "Cloning and characterization of neurohypophysial transcription factors involved in development and function of the hypothalamo/hypophysial axis."
2. 1998-2002: Marjan Kromkamp: "Expression patterns of genes involved in brain development and human brain disorders".
3. 2000-2004: Simone Smits: Analysis of Pitx3 mutants.
4. 2000-2004: Lars van der Heide: PKB Signaling in the developing and adult nervous system
5. 2001-2005: Patrick Wijchers: Cloning of Forkhead genes related to midbrain development and function.
6. 2003-2007: Koen Hornman: Development and function of the mesDA system, involvement of Pitx3.
7. 2004-2008: Frank Jacobs: Identification of target genes of the homeodomain gene Pitx3.
8. 2007-2011: Teresa Alves Dos Santos: Identification of Pitx3 regulated genes in midbrain dopamine neurons
9. 2007-2012: Elisa Hoekstra: Molecular coding of mdDA neurons during development
10. 2009-2010: Kerstin Iffland: Role of RA through DLK1 signalling in the development of mdDA neurons (left the lab after 1 year).
11. 2009-2013: Jesse Veenfliet, The role of RA signalling in subset specification of mdDA neurons.
12. 2011-2015: Ricardo Paap, Cortical development, the role of FoxO6 in stem cell maintenance.
13. 2011-2015: Simone Mesman, Ventricular zone coding of the mesodiencephalic area
14. 2011-2015: Willemieke Kouwenhoven, Crosstalk between En1, Pitx3 and Nurr1 in development of mdDA neurons
15. 2013-2017: Iris Wever, Epigenetic influence of Lim homeodomain proteins in neuronal specification of mdDA neurons.
16. 2013-2017: Erik van Heesbeen, Epigenetic mechanisms in neuronal specification and differentiation.
17. 2014-2018: Gerrald Lodewijk, PhD 2021
18. 2015-2019: Nina Haring, PhD 2020
19. 20167-2021: Eddie Robinson, Mc11 in control of life and death of dopamine neurons, PhD 2021
20. 2017-2021: Swip Draaijer, Role of FoxO6 in stem cell maintenance and cortical development
21. 2018-2022: Jesse Stoop, modulation of TH production in midbrian DA neurons
22. 2018-20222: Erik Douma, modulation of TH production in midbrian DA neurons
23. 2020-2024: Reinofke de Vis, Mc11 in the regulation of celdeath in dopamine neurons
24. 2020-2024: Luis Alves, Role of TCF in cortical and medulla development.

### 5.4.2 Promoter:

1. Co-promoter of Cerial Asbreuk (PhD in 2002).
2. Co-promoter of Marjan Kromkamp (PhD in 2002).
3. Co-promoter of Lars van de Heide (PhD in 2004).
4. Co-promoter of Simone Smits (PhD in 2005)
5. Co-promoter of Patrick Wijchers (PhD in 2005).
6. Co-promoter of Frank Jacobs (PhD in 2009).
7. Promoter of Teresa Alvers dossantos (PhD in 2011).
8. Promoter of Elisa Hoekstra (PhD in 2012).
9. Promoter of Jesse Veenvliet (PhD in 2014)
10. Promoter of Willemieke Kouwenhoven (PhD in 2016)
11. Promoter of Ricardo Paap (PhD in 2017)
12. Promoter of Simone Mesman (PhD in 2016)
13. Promoter of Iris Wever (PhD in 2018)
14. Promoter of Erik van Heesbeen (PhD in 2021)
15. Promoter of Gerald Lodewijk (PhD in 2021)
16. Promoter of Nina Haring (PhD in 2020)
17. Promoter of Eddie J Robinson (PhD in 2021)
18. Promoter of Swip Draaier (PhD in 2022)
19. Promoter of Jesse Stoop (PhD in 2022)
20. Promoter of Erik Douma (PhD in 2023)
21. Promoter of Luis Baiona Alves (PhD 2025)
22. Promoter of Reinofka van de Vis (PhD in 2025)
23. Promotor of Tanne van der Wal (2024)

### 5.4.3 Master Students:

1. 1998-1999: Kyra Campbell: Cloning of Xenopus Pitx3.
2. 1999-2000: Leontien Spierings: Analysis of Pitx3 protein in Human SNc in healthy controls and Parkinsonian brain.; Erik Baaijens: Analysis of new markers in the mesDA system; Max Custers: Provision of cRNA probes for ISH analysis of mesDA markers.
3. 2001-2002: Frank Jacobs: Cloning of homeodomain and forkhead genes from the mesDA systems.; Wiebe Hielkema: Recombinant protein production/purification and generation of antibodies.; Suzanne van der Nobelen: Subtraction library screening of wt and AK mesDA tissue.; Koen Hornman: Generation of a TH-Pitx3 knock-in construct.
4. 2004: Rolf Meijer: analyzing the molecular code on developing midbrain dopaminergic neurons; Joris van Arnsbergen: Analyzing signaling cascades in midbrain dopaminergic neurons; Marijke de Backer: mGluR distribution in the developing and adult mouse brain.
5. 2005/2006: Joanna Korecka, Hanneke Verstegen
6. 2007: Susan van Erp, Mark Mizze, Thomas Gora.
7. 2008: Louk van der Kallen, Willem de Munnik, Jesse Veenvliet.
8. 2009: Diewertje Bink, Gerard Scheppink.
9. 2010; Simone Mesman, Ricardo Paap, Roel Neijts
10. 2011; Roel Neijts, Iris Wever; Cindy Wagemans
11. 2012-current; My team harbors 10-15 master students very year, next to max. 5 bachelor students

#### 5.4.4 Other trainees

1. 1997-1999: Dr. Pilar Cazorla: "Characterisation of the novel homeodomain gene Pitx3".
2. 1997-1998: Prof. Dr. Michael Selmanoff : "Cloning of novel homeodomain genes involved in the development and function of the hypothalamus".
3. 2004-2007: Dr. Simone Smits: Development of the mesDA system.
4. 2005-2007: Dr. Cornelle Noorlander: The role of prenatal antidepressant use for the setting of the serotonin system.
5. 2008-2011: Dr. Koushik Chakrabarty: Gene profiling of early developmental events in mesodiencephalic dopaminergic neurons.
6. 2009-2010: Dr. Evelyn Groot, Early dopaminergic subset specification on the mesodiencephalic-ventricular zone.
7. 2009-2012: Dr. Wadia Almirza, Unraveling the key players in RA signaling during mdDA neurodevelopment.
8. 2011-2013: Dr. E. Hoekstra, Role of Lmx1a and Lmx1b in mdDA neuronal specification.
9. 2011-2013: Dr. L. van der Heide, TGF-beta signalling in mdDA neurons.
10. 2018-2020: Dr. S. Mesman, transcriptional coding of neuronal development.

#### 5.5 Selection of invited lectures

1. March 5, 1999: Molecular cascades in development of the mesDA system; Invited by Andreas Hartmann, INSERM, Paris, France
2. March 19, 1999: Cloning and analysis of homeobox genes in CNS development; Invited by Dr. M. Linskens, University of Groningen, The Netherlands
3. May 19, 1999: Homeodomain transcription factors and MesDA development; Invited by Joost Verhagen, Netherlands Brain Institute, Amsterdam, The Netherlands
4. December 10, 1999: Molecular cascades in mesDA development and function; Invited by Dr. Jochem Graw, Max Plank Institute, Munich, Germany
5. April 6-9, 2000: Molecular cascades in mesDA development and function; Invited by: Professor K.V. Sudakov, Russian Academy of Medical Sciences, P.K. Anokhin Institute of Normal Physiology, Moscow, Russia.
6. November 24, 2000: New directions in the development and function of the mesencephalic dopaminergic system; Invited by: Dr. Bert Joosten, Department of Neurology, University Medical Center, Utrecht, The Netherlands
7. June 9-14, 2002: Development of the substantia nigra pars compacta is depending on the homeodomain gene Pitx3; Invited by: The 2002 Dopamine Conference in Portland, Oregon, USA
8. January 31, 2003: Development of the substantia nigra pars compacta is depending on the homeodomain gene Pitx3; Invited by: Dutch Neuro Federation Research Class 2003
9. July 17, 2003: Development of the substantia nigra pars compacta is depending on the homeodomain gene Pitx3; Invited by: Dr. Horst Simon, Department of Anatomy and Cell Biology III, University of Heidelberg, Heidelberg, Germany.
10. November 8-12, 2003: Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3; Invited by: The 2003 American Society of Neuroscience Meeting, New Orleans, USA
11. December 18, 2003: Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3; Invited by: Dr. Silke Rinkwitz, University of Oldenburg, Oldenburg, Germany
12. May 27, 2004: The homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra; Invited by: Prof. Dr. Luis Puelles, Department of Human Anatomy and Psychobiology, Faculty of Medicine, University of Murcia, Murcia, Spain.
13. June 6, 2005: The role of Pitx3 in survival of midbrain dopaminergic neurons; Invited by: The 16th International congress on Parkinson disease and related disorders, The world congress on Parkinson disease, Berlin, Germany
14. March, 8, 2006: Developmental origin and fate of meso-diencephalic dopamine neurons; Invited by Ronald van Kesteren, VU, Amsterdam The Netherlands



15. July 3, 2006: Origin and subset specification of mesodiencephalic dopaminergic neurons; Invited by: International Symposium entitled Development of Neurotransmitter Systems. The Collaborative Research Center - Sonderforschungsbereich 488 of the German Research Foundation - Molecular and Cellular Bases of Neural Development and the Interdisciplinary Center for Neuroscience (IZN) at Heidelberg University
16. May 30-June 2, 2007: Early development and neuronal specification of mesodiencephalic dopaminergic neurons; Invited by Thomas Perlmann for the symposium: 50 years of Dopamine, Stockholm, Sweden.
17. August 30-Sept 1, 2007: The role of Ahd2 in neuronal specification and maintenance of SNc neurons; Invited by Anders Bjorklund and Thomas Perlmann for the Nobel symposium: Development and Engineering of Dopamine Neurons: From Genes to Therapy, Stockholm, Sweden.
18. November 30-Dec 1, 2007: A Pitx3 regulatory network in development and maintenance of mesodiencephalic dopamine neurons. Invited by I. Dori and G. C. Papadopoulos for the symposium: brain: from cells to behavior, Tessaloniki, Greece.
19. January 22-27, 2008: Visiting professor, V International Course on Morphological Interpretation in Neuroembryology, Murcia Spain. Invited by Luis Puelles.
20. April 17, 2008: Vulnerability of dopaminergic neurons: a Pitx3 regulatory network, Heinrich-Heine-University, Duesseldorf, Germany.
21. June 4-6, 2008: Molecular programming of mesodiencephalic dopaminergic neurons, 2008 Dutch Endo-Neuro-Psycho meeting, Doorwerth, The Netherlands.
22. November 26, 2008: A Pitx3 induced gene regulatory network in the formation and maintenance of substantia nigra dopamine neurons, 2008 RMI symposium, Utrecht, The Netherlands.
23. Januari 7, 2009: A Pitx3 induced gene regulatory network in the formation and maintenance of substantia nigra dopamine neurons, Invited by Siew-lan Ang, MRC, London, UK
24. Februari 6, 2009: How to build the central nervous system, Emma Andersson, Karolinska Intitute, Stockholm, Sweden (Opponent of Thesis defence of Emma Andersson).
25. December 3, 2009: A Pitx3 regulated network in the differentiation program of mdDA neurons, FP7 “mdDAneurodev” consortium meeting, Utrecht, The Netherlands.
26. December 11, 2009: Subset specification in the mdDA neuronal population, Judith Homberg, University of Nijmegen, Nijmegen, The Netherlands.
27. May 6, 2010: A Pitx3 regulated network in the differentiation program of mdDA neurons, Thomas Perlmann, karolinska Intitute, Stockholm, Sweden.
28. June 17, 2010: Development of the vertebrate mesodiencephalic dopaminergic system, Stefano Gustincich, DOPAMINET consortium meeting, London, UK.
29. September 4, 2010: Retinoic acid dependent and independent Pitx3 driven mdDA neuronal differentiation, Ernest arenas, 8th international Stem cell School in regenerative medicin 2010, karolinska Intitute, Stockholm, Sweden.
30. April 15, 2011: A Pitx3 regulated network in the development of mdDA neurons, Alain Prochianz, Paris, France.
31. April 28-29, 2011: A Pitx3 regulated network in the development of mdDA neurons, Shared “Dopaminet” and “mdDAneurodev” FP7-meeting, Freiburg, Germany
32. June 17, 2011: A Pitx3 regulated network in the development of mdDA neurons, International Translational Neuroscience Conference, Kaunas, Lituania.
33. June 28, 2011: Retinoic acid dependent and independent Pitx3 driven mdDA neuronal differentiation, FEBS symposium, Torino, Italy.
34. November 11, 2011: A Pitx3 regulated network in the development of mdDA neurons., Sjef Copray, Molecular Medicin Seminars Series 2011, Groningen, The Netherlands.
35. Januari 27, 2012: A Pitx3 regulated network in the development of mdDA neurons., Tania Vitalis, Paris, France.
36. February 14, 2012: A Pitx3 mediated program of dopaminergic subset-specification., Eric Bellefroid, Bruxelles, Belgium.

37. March 15/16, 2012: A Pitx3 mediated program of dopaminergic subset-specification., Alain Prochianz, Paris, France. International meeting on developmental neuroscience hosted by Alain Prochianz's Institution (Smidt, co-organiser).
38. April 16, 2012: Molecular specification of mdDA neuronal subsets., Antonio Simeone, CNRS, Italy
39. May 3, 2012: Molecular specification of mdDA neuronal subsets., Anders Bjorklund, Annual Neuroscience meeting Lund University, Lund, Sweden
40. May 24, 2013: Molecular specification of mdDA neuronal subsets, invited speaker to session "TRANSCRIPTION FACTORS AS MEDIATORS OF DOPAMINE NEURODEGENERATION IN PARKINSON'S DISEASE" in the meeting "DOPAMINE 2013, Alghero, Italy"
41. November 8-13, 2013: Molecular specification of mdDA neuronal subsets, invited speaker, SFN 2013, San Diego, USA
42. September 20-23, 2016: Genetic programming of dopaminergic subsets, invited speaker, World Parkinson congress 2016, Portland, Oregon, USA.
43. May 13-15, 2019 : Genetic programming of dopaminergic subsets, invited speaker, Interational Dopamine meeting, Krete, Greece.
44. September 24-25, 2020: Involvement of Epigenetic changes in Parkinson's, invited speaker, Accelerating breakthroughs in research and improving care in Parkinson's: Parkinson's UK Research Conference 2020 (online).

## **5.6 Selection of current and past collaborations with (foreign) academic groups**

1. Function of the Engrailed 1 and 2 genes: Dr. Horst H. Simon, University of Heidelberg, Heidelberg, Germany. (Manuscript is published)
2. Analysis of cRet genetically modified mice, Edgar Kramer, Max Planck Institute of Neurobiology, Martinsried, Germany. (Manuscript is published)
3. Serotonin action in the developing CNS, Hans van Hooft, AMC, Amsterdam The Netherlands. (2 Manuscripts Published)
4. Developmental effects of prenatal SSRI exposure, Gerard Visser, Neonatologie, WKZ, Utrecht. The Netherlands (Manuscript published) Until 2011
5. Genetics of Parkinson's Disease, Peter Heutink, VU, Amsterdam, The Netherlands Until 2011
6. FP7 partners in mdDAneurodev project: O. Marin; T. Perlmann, W. Wurst, A. Simeone, W. Driever, A Prochianz and J. Pasterkamp. EU project until 2012
7. Role of Foxd2 in development of mdDA neurons, Tsutomu Kume, Ph.D. Assistant Professor Department of Medicine Vanderbilt University Medical Center 332 PRB, Nashville, TN 37232-6300, USA (Manuscript in preparation)
8. Analysis of the DLK-1 knock out, Y. Wang and H.S. Sul, Department of Nutritional Science and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA. (Manuscript published)
9. Analysis of connectivity in the Pitx3 ko, Sharon Kolk, PhD, RUN, Nijmegen.
10. Maternal inflammation and mdDA neuronal development, role of epigenetics, Gerard O'Keeffe, Department of Anatomy & Neuroscience, Room 1.11, Biosciences Institute, University College Cork, Cork, Ireland.
11. Identification of MiRNAs in mdDA neurons, Gian Carlo Bellinchi, Institute of Genetics and Biophysics, Naples, Italy (Manuscript published 2018).
12. Chip-seq analysis on novel chimeras of Dot11, Fred van leeuwen, NKI, Amsterdam, The Netherlands
13. Role of H3K79methylation level in neuronal development, Dr L.Trudeau and Dr. W. Kouwenhoven, Montreal, Canada.
14. H3K79methylation kinetics, Dr. F. van Leeuwen, NKI, Amsterdam, The Netherlands

## **5.7 Selection of management activities**

### **5.7.1 Research management**

2001-present:

- Team leader of the Development and function of the mesencephalic dopaminergic system research team (start 2001).
- Member of the organizing committee: Dutch Neurofederation Research Class on Brain Development (2003).
- Chairman: Rudolf Magnus Institute of Neuroscience Summerschool 2003.
- Co-Coordinator of the Section Neurodevelopment of the Rudolf Magnus Institute of Neuroscience.
- Member of organizing committee: Rudolf Magnus Institute of Neuroscience Summerschool 2004.
- Member of the NWO-ALW open program committee (2006)
- Coordinator of a FP7 EU-grant project (2008-2011), medium sized EU-research project.
- Head of the research platform “Neurodevelopment” (start 2008).
- Coordinator of the Neurodevelopment section of the Rudolf Magnus Institute (start 2008).
- Chairman of the NWO-ALW-VENI committee (2009 and 2010).
- Member of the University Utrecht VICI coachingscommittee 2011.
- Chairman of the ALW-VIDI committee (2011-2014).
- Chairman of the Examination board Bachelor program “Psychobiology” at UvA (2012-2015).
- Director Neurobiology master program cluster UvA (2012-2015).
- Coordinator within the National (dutch)education on Animal Experimentation team (2012-2016).
- Director of the Swammerdam Institute for Life Sciences (SILS, ~ 250 fte), UvA, The Netherlands (2015-2020).
- Chair of a faculty task force towards staffing and finance in the bachelor program Psychobiology (2018).
- Core developer of RPA “Urban Mental Health” UvA, Amsterdam, The Netherlands, (2019)
- Chair of a foundation to stimulate scientific research in the biochemistry domain (Stichting ter bevordering van het wetenschappelijke onderzoek in de biochemie) (2020-current)
- Member of the University of Amsterdam Senate (2021-current).
- Member of the ICT committee FNWI, UvA (2021-current)

### **5.7.2 IT management**

- Adviser of IT steering group in the medical department, University of Utrecht. (1998-2002)
- Representative of the section molecular neuroscience for IT-support. (1998-2002)
- Interim IT-coordinator Division "Hersenen" of the University Medical Center, Utrecht -until 2005
- Developer/System administer of a Linux server for molecular genetics software -until 2005.
- IT adviser for the department neuroscience and pharmacology, University Medical Center, Utrecht.
- Development and implementation of a new IT infrastructure for the department neuroscience and pharmacology of the University Medical Center, Utrecht -until 2004.
- Manager IT in the department neuroscience and pharmacology, University Medical Center, Utrecht (2004-2011)
- Linux system manager (mainly OpenSuse; 2005-current)

### 5.7.3 Management trainings/activities

- Management training 2 days full time. Academic leadership (2007).
- Personal coaching (every two months one session, 2007-now)
- Interim manager/external adviser of the MT, department of Domestic animals, UU, The Netherlands (2009)
- Communication training 2011 (1 day, buro Beysterveld)

### 5.7.4 Personal management

- Board member of the Budo School on Martial Arts, De Mattekloppers, University of Groningen (1992-1996)
- Chairman of the Budo school on Martial Arts, De Mattekloppers, University of Groningen (1994-1996)
- Chairman of the MR, Driekoningen school, De Meern, The Netherlands (2008-2012)
- Advisor of the PVDV acquisition committee (2011-2014)

## 6 Business development

- 2017 Bootcamp course business development at "Ace Venture Labs", The Netherlands
- Co-founder of "Macrobian-Biotech BV", a company for pre-clinical drug development.
- CEO of Macrobian Biotech BV.

## 7 Educational experience

- 1989: Assistant to the course: Science and Society.
- 1991-1994: Development and application of the practical course: Biochemistry for Biologist (1 month).
- 1996-2000: Curriculum health-care (UU): Practical Kinetics of Pharmacology
- 1999, 2000: Development and lecturing: "Disease of the central nervous system".
- 2001: Development and lecturing, PhD course Neuroscience; Development and lecturing, KNAW advanced course on Neurogenomics; Development and lecturing: "Disease of the central nervous system"; Development and lecturing: Advanced Course in Neuroscience (PhD course); Lecturing brain development and function of the mesDA system: in PhD course "Neuroscience", University of Amsterdam, Netherlands Brain Institute.
- 2002/2003: Development and lecturing: Advanced Course in Neuroscience.; Development and lecturing: Neuroscience Course. ; Development and lecturing: "Disease of the central nervous system".; Organizer Research Class 2003.; Chairman: Rudolf Magnus Institute of Neuroscience Summerschool 2003.; Development and lecturing: Masters Neuroscience , elected prestigious master.
- 2004: Coordinator : Advanced Course in Neuroscience.; Development and lecturing: Neuroscience Course. ; "Meet the expert" sessions and involved in study material selection for: "Development and developmental disturbances of the Central Nervous System (CNS)".; Member of the organizing committee: Rudolf Magnus Institute of Neuroscience Summerschool 2004.; Development and lecturing: Masters Neuroscience (prestigious master).
- 2001-2011 Advanced neuroscience course for bachelor students; practical and lectures, new practical and additional lectures were developed in 2009.
- 2005-2010 Neuroscience Course: Development and lecturing; Development and developmental disturbances of the Central Nervous System (CNS): Meet the expert" sessions and involved in course development;
- 2005-2010 Prestigious Master Neuroscience: Development, lecturing, practicals and assignment tutor.
- 2006-2010 Visiting professor developmental neuroscience master course, VU, Amsterdam
- 2008 Visiting professor, V International Course on Morphological Interpretation in Neuroembryology, Murcia Spain.
- 2009 Lecturer at the ONWA PhD course, Utrecht, The Netherlands.

- 2010 Lecturer and practicals (TUE) in the PhD course “Developmental Neurobiology”
- 2011 Lecturer/trainer in the RMI summerschool: “Grant writing”.
- 2009-2010: Lecturer at high schools (“Atheneum”, year 6); Dutch Brain week
- 2010-2011: Panel member during information day for the NWO VI grant-program.
- 2012: BKO certification
- 2013- current: Principle developer/lecturer; master program (2 years) “Molecular NeuroSciences (MNS)” UvA
- 2013-current: Lecturer/developer Genetic programming in neurodevelopment (4 weeks) in MNS master course, UvA
- 2012-current: Lecturer/developer Introduction neurodevelopment (1 week) in Neurobiology track medical biology bachelor, UvA.
- 2012-current: Lecturer/developer Neurodevelopment and developmental neuropsychology (3 days) psychobiology bachelor year 2 course, UvA
- 2012-current: Lecturer/developer Molecular techniques (1 day), psychobiology third year course, UvA
- 2011-current: Lecturer/developer Grant writing (1/2 day): Summerschool rudolf magnus institute for neuroscience, UU.
- 2008-current; Lecturer/developer ONWAR course “Molecular Neurobiology”, VU-NIN.
- 2013-2015: Principle developer of a certified Art9 course according the Dutch law on animal experimentation.
- 2016: SKO certification

## 8 Selected honors

1. USA National Parkinson Foundation, Richard E. Heikkila Research Scholar Award (award for the best research proposal of 1998).
2. Personal post-doc grant (NWO-MW) (the current Veni award)
3. Rudolf Magnus Institute for Neuroscience Research Award (2000). For innovating research on the development of the mesencephalic dopaminergic system.
4. The Netherlands Brain Foundation (HSN) Award for outstanding research performance (2001).
5. High-potential award, University of Utrecht (2004).
6. Vidi award (eligible for funding), NWO-MW, The Netherlands (2004).
7. Rudolf Magnus Institute for Neuroscience Research Award to Frank Jacobs and Simone Smits (2007). Best publication in 2007: **Jacobs FM, Smits SM, Noorlander CW, von Oerthel L, van der Linden AJ, Burbach JP and Smidt MP.** Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. *Development*. 2007 Jul;134(14): 2673-84. IF 8
8. Vici award, NWO-ALW, The Netherlands (2009).

## 9 List of publications, books and patent applications

### 9.1 Pre-print published manuscripts

1. Iris Wever, Pablo Largo Barrientos, Elisa J. Hoekstra and Marten P. Smidt (2018) Lmx1b influences correct post-mitotic coding of mesodiencephalic dopaminergic neurons. bioRxiv 441915; doi: <https://doi.org/10.1101/441915>
2. Iris Wever, Cindy M.R.J. Wagemans and Marten P. Smidt (2018) EZH2 is essential for fate determination in the mammalian Isthmic area. bioRxiv 442111; doi: <https://doi.org/10.1101/442111>
3. Iris Wever, Lars von Oerthel, Cindy M.R.J. Wagemans and Marten P. Smidt (2018) EZH2 influences mdDA neuronal differentiation, maintenance and survival. bioRxiv 442236; doi: <https://doi.org/10.1101/442236>
4. Simone Mesman, Reinier Bakker, Marten Smidt (2018) Tcf4 encodes cortical differentiation during development Simone Mesman, Reinier Bakker, Marten Smidt bioRxiv 470385; doi: <https://doi.org/10.1101/470385>

## 9.2 Peer refereed international journals (impact factors (IF) are listed)

- Almost all papers are in the top 25 % of journals (based on mean impact factor, 5 year).
1. Tcf4 Is Involved in Subset Specification of Mesodiencephalic Dopaminergic Neurons (2021) Simone Mesman , Iris Wever and Marten P. Smidt. *Biomedicines* 9(3), 317; <https://doi.org/10.3390/biomedicines9030317>
  2. Mice hypomorphic for Pitx3 define a minimal dopamine neuron population sufficient for entraining behavior and metabolism to scheduled feeding despite free-running light-entrained circadian rhythms. (2021) Lori L. Scarpa, Brad Wanken, Marten Smidt, Ralph E. Mistlberger, and Andrew D. Steele. *Cell Reports in press./bioRxiv*
  3. Cue and reward evoked dopamine activity is necessary for maintaining learned Pavlovian associations. (2021) Ruud van Zessen, Jacques Flores, Timon Eekel, Siem van den Reijen, Bart Lodder, Azar Omrani, Marten Smidt, Geoffrey van der Plasse, Geert Ramakers, Garret Stuber, and Roger Adan. *J Neurosci.* Apr 19;JN-RM-2744-20. doi: 10.1523/JNEUROSCI.2744-20.2021.
  4. ZNF91 deletion in human embryonic stem cells leads to ectopic activation of SVA retrotransposons and up-regulation of KRAB zinc finger gene clusters. (2021) Haring NL, van Bree EJ, Jordaan WS, Roels JRE, Sotomayor GC, Hey TM, White FTG, Galland MD, Smidt MP, Jacobs FMJ. *Genome Res.* 2021 Mar 15. doi: 10.1101/gr.265348.120. Online ahead of print. PMID: 33722937
  5. Advancing urban mental health research: from complexity to action (2021) J.M. van der Wal, C.D. van Borkulo, M. Deserno, J. J. F. Breedvelt, M. Lees, C. Lokman, Prof. D. Borsboom, Prof. D. Denys, R. van Holst, Prof. M. Smidt, Prof. K. Stronks, Prof. P.J. Lucassen, Prof. J.C.M. van Weert, Prof. P.M.A. Sloot, Prof. C.L.H. Bockting, & Prof. R.W. Wiers. *Lancet Psychiatry in press*
  6. Tcf4 encodes cortical differentiation during development. (2020) Simone Mesman, Reinier Bakker, Marten Smidt. *MCN Volume 106*, July 2020, 103502, <https://doi.org/10.1016/j.mcn.2020.103502>
  7. Acquisition of the Midbrain Dopaminergic Neuronal Identity. (2020) Mesman S, Smidt MP. *Int J Mol Sci.* 2020 Jun 30;21(13):4638. doi: 10.3390/ijms21134638. PMID: 32629812
  8. MCL1 as a Therapeutic Target in Parkinson's Disease? (2019) Edward J.Robinson, SebastianAguiar, Marten P.Smidt and Lars P.van der Heide. *Trends Mol. Med.* 25(12):1056-1065. <https://doi.org/10.1016/j.molmed.2019.08.009>
  9. Characterization of transgenic mouse models targeting neuromodulatory systems reveals organizational principles of the dorsal raphe. (2019) Daniel Cardozo Pinto, Hongbin Yang, Iskra Pollak Dorocic, Johannes de Jong, Vivian Han, James Peck, Yichen Zhu, Christine Liu, Kevin Beier, Marten P. Smidt, and Stephan Lammel. *Nat. Comm.* 10:4633; <https://doi.org/10.1038/s41467-019-12392>.
  10. Lmx1b Influences Correct Post-mitotic Coding of Mesodiencephalic Dopaminergic Neurons. (2019) Iris Wever, Pablo Largo-Barrientos, Elisa J. Hoekstra and Marten P. Smidt, *Front. Mol. Neurosci.*, 14 March 2019 | <https://doi.org/10.3389/fnmol.2019.00076>
  11. EZH2 is essential for fate determination in the mammalian Isthmic area. (2019) Iris Wever, Cindy m. Wagemans and Marten P. Smidt. *Front. Mol. Neurosci.* | doi: 10.3389/fnmol.2019.00076
  12. Entanglement of Genetics and Epigenetics in Parkinson's Disease (2019) H. J. van Heesbeen and Marten P. Smidt, *Front. Neurosci.* | doi: 10.3389/fnins.2019.00277.
  13. EZH2 Influences mdDA Neuronal Differentiation, Maintenance and Survival.(2019) Wever I, von Oerthel L, Wagemans CMRJ, Smidt MP. *Front Mol Neurosci.* 2019 Jan 17;11:491. doi: 10.3389/fnmol.2018.00491. eCollection 2018.
  14. Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1. (2018) Robinson EJ, Aguiar SP, Kouwenhoven WM, Starmans DS, von Oerthel L, Smidt MP, van der Heide LP. *Cell Death Discov.* 4:107. doi: 10.1038/s41420-018-0125-7.
  15. Roberto De Gregorio, Salvatore Pulcrano, Claudia De Sanctis, Floriana Volpicelli, Ezia Guatteo, Lars Von Oerthel, Roberta Esposito1, Rosa Maria Piscitelli, Carla Perrone Capano, Valerio Costa1, Dario Greco, Marten Smidt, Umberto di Porzio, Massimiliano Caiazzo, Nicola Biagio Mercuri, Meng Li and Gian Carlo Bellenchi (2018) miR-34b/c enhances mesencephalic dopaminergic neuron differentiation by negatively modulating Wnt signaling *Stem Cell Reports* 1-, 1-14; IP 7.5
  16. Mesman S, Krüse SJ, Smidt MP. (2018) Expression analyzes of early factors in midbrain differentiation programs. *Gene Expr Patterns.* 27:8-15. doi: 10.1016/j.gep.2017.09.001. Epub 2017

17. Simone Mesman and Marten P. Smidt (2017) Tcf12 Is Involved in Early Cell-Fate Determination and Subset Specification of Midbrain Dopamine Neurons. *Front. Mol. Neurosci.* 10:353. doi: 10.3389/fnmol.2017.00353 IP 6
18. Smidt MP. (2017) Molecular Programming of Mesodiencephalic Dopaminergic Neuronal Subsets. *Front Neuroanat.* 2017 Jul 19;11:59. doi: 10.3389/fnana.2017.00059.
19. Kouwenhoven WM, von Oerthel L, Smidt MP (2017) Pitx3 and En1 determine the size and molecular programming of the dopaminergic neuronal pool. *PLoS One.* 12(8):e0182421. doi: 10.1371/journal.pone.0182421
20. Miguel A.P. Oliveira, Rudi Balling, Marten P. Smidt, Ronan M.T. Fleming (2017) Embryonic development of selectively vulnerable neurons in Parkinson's disease. *Nature Partner Journal (NPJ): Parkinson's Disease*, Jun 26;3:21. doi: 10.1038/s41531-017-0022-4.
21. Mesman S, van Hooft JA and Smidt MP (2017) Mest/Peg1 is essential for the development and maintenance of a SNc neuronal subset. *Front. Mol. Neurosci.* | doi: 10.3389/fnmol.2016.00166 IP 5
22. Paap RH, Oosterbroek S, Wagemans CM, von Oerthel L, Schellevis RD, Vastenhouw-van der Linden AJ, Groot Koerkamp MJ, Hoekman MF, Smidt MP. (2016) FoxO6 affects Plxn4-mediated neuronal migration during mouse cortical development. *Proc Natl Acad Sci U S A* vol. 113 no. 45, E7087–E7096 IP 10
23. Willemieke M. Kouwenhoven and Marten P. Smidt. (2016) Commentary: engrailed 1 shapes the dopaminergic and serotonergic landscape through proper Iso maintenance and function *J. Neurology & Neuromedicine* 1(5), 1-3.
24. Kouwenhoven WM, Veenliet JV, van Hooft JA, van der Heide LP, Smidt MP Engrailed 1 shapes the dopaminergic and serotonergic landscape through proper isthmus organizer maintenance and function. (2016) *Biol Open* 5(3):279-88. doi: 10.1242/bio.015032. IP 4
25. van der Heide LP, Wijchers PJ, von Oerthel L, Burbach JP, Hoekman MF, Smidt MP. (2015) FoxK2 is required for cellular proliferation and survival. *J Cell Physiol.* 230(5):1013-23. doi: 10.1002/jcp.24828. IP 5
26. Veenliet JV, Smidt MP. (2014) Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives. *Cell Mol Life Sci.* 71(24):4703-27 2014 Jul 27. [Epub ahead of print] IP 6.
27. Inês Chaves, Gijsbertus T.J. van der Horst, Raymond Schellevis, Romana M. Nijman, Marian Groot Koerkamp, Frank C.P. Holstege, Marten P. Smidt and Marco F.M. Hoekman (2014) FoxO3 in control of the hepatic circadian oscillator via direct regulation of Clock. *Current Biology* 2;24(11):1248-55. doi: 10.1016/j.cub.2014.04.018. IP 11
28. Simone Mesman, Lars von Oerthel and Marten P. Smidt (2014) Mesodiencephalic dopaminergic neuronal differentiation does not involve GLI2A-mediated SHH-signaling and is under the direct influence of canonical WNT signaling. *PLoSOne* May 27;9(5):e97926. doi: 10.1371/journal.pone.0097926. eCollection 2014. IP 4
29. Marlies Oostland, M. Renate Buijink, Guus M. Teunisse, Lars von Oerthel, Marten P. Smidt, Johannes A. van Hooft.(2014) Distinct Temporal Expression of 5-HT1A and 5-HT2A Receptors on Cerebellar Granule Cells in Mice. *Cerebellum* 13(4):491-500. doi: 10.1007/s12311-014-0565-4. IP 3.
30. Reinhard Roessler, Sebastien A Smallwood, Jesse V Veenliet, Petros Pechlivanoglou, Suping Peng1, Koushik Chakrabarty, Marian JA Groot-Koerkamp, R. Jeroen Pasterkamp, Evelyn Wesseling, Gavin Kelsel, Erik Boddeke Marten P Smidt and Sjef Copray. (2014) Detailed analysis of the genetic and epigenetic signature of iPS cell-derived mesodiencephalic dopaminergic neurons. *Stem Cell Reports* 2(4):520-33. doi: 10.1016/j.stemcr.2014.03.001 (Cell press) IP 7.5
31. Smidt MP, van Hooft JA. Subset specification of central serotonergic neurons. (2013) *Front Cell Neurosci.* 7:200. Review. IP 5
32. Smits SM, von Oerthel L, Hoekstra EJ, Burbach JPH, Smidt MP (2013) Molecular Marker Differences Relate to Developmental Position and Subsets of Mesodiencephalic Dopaminergic Neurons. *PLoS ONE* 8(10): e76037. doi:10.1371/journal.pone.0076037 IP 4.5
33. Hoekstra EJ, von Oerthel L, van der Heide LP, Kouwenhoven WM, Veenliet JV, Wever I, Jin YR, Yoon JK, van der Linden AJ, Holstege FC, Groot Koerkamp MJ, Smidt MP. (2013) Lmx1a Encodes a Rostral Set of Mesodiencephalic Dopaminergic Neurons Marked by the Wnt/B-Catenin Signaling Activator R-spondin 2. *PLoS One.* 2013 Sep 16;8(9):e74049. doi: 10.1371/journal.pone.0074049. IP 4.5
34. Jesse V Veenliet\*, Maria TM Alves dos Santos\*, Willemieke M Kouwenhoven, Lars von Oerthel, Jamie L Lim, Annemarie JA van der Linden, Marian JA Groot Koerkamp, Frank CP Holstege and Marten P Smidt (2013) En1 and Pitx3 interplay in dopaminergic subset-specification. *Development* 140, 3373-3384 (2013) doi:10.1242/dev.094565. \*shared first authorship IP7

35. Mareen Engel, Marten P Smidt\*, Johannes A Van Hooft\* (2013) The serotonin 5-HT<sub>3</sub> receptor: a novel neurodevelopmental target. *Frontiers in Neuroscience* in press. Shared last author, IP 5
36. Lars P. van der Heide and Marten P. Smidt (2013) The BCL2-code to dopaminergic development and Parkinson's disease. *Trends Mol Med.* 19(4):211-6. IP 11.
37. van Heesbeen HJ, Mesman S, Veenvliet JV, Smidt MP. (2013) Epigenetic mechanisms in the development and maintenance of dopaminergic neurons. *Development.* 2013 Mar;140(6):1159-69. doi: 10.1242/dev.089359. IP 7.
38. Nott A, Nitarska J, Veenvliet JV, Schacke S, Derijck AA, Sirko P, Muchardt C, Pasterkamp RJ, Smidt MP, Riccio A. (2013) S-nitrosylation of HDAC2 regulates the expression of the chromatin-remodeling factor Brm during radial neuron migration. *Proc Natl Acad Sci U S A.* 110(8):3113-8. IP 10.
39. Hoekstra EJ, Mesman S, de Munnik WA, Smidt MP. (2013) Lmx1b Is Part of a Transcriptional Complex with PSPC1 and PSF. *PLoS One.* 2013;8(1):e53122. doi: 10.1371/journal.pone.0053122. Epub 2013 Jan 4. IP 5
40. Hoekstra EJ, von Oerthel L, van der Linden AJ, Smidt MP. (2012) Phox2b influences the development of a caudal dopaminergic subset. *PLoS One.* 2012;7(12):e52118. doi: 10.1371/journal.pone.0052118. Epub 2012 Dec 14. IP 5
41. Elisa J Hoekstra, Lars von Oerthel, Annemarie J A van der Linden, Raymond D Schellevis, Gerard Scheppink, Frank C.P. Holstege, Marian J Groot-Koerkamp, Lars P van der Heide2, Marten P Smidt (2012) Lmx1a is an activator of Rgs4 and Gbr10 and is responsible for the correct specification of rostral and medial mdDA neurons. *Eur J Neurosci.* 2012 Oct 29. doi: 10.1111/ejn.12022. IP 3.6
42. Frank Meye, Ruud van Zessen, Marten Smidt, Roger Adan, and Geert Ramakers (2012) Morphine withdrawal enhances constitutive mu-opioid receptor activity in the ventral tegmental area. *J Neurosci.* 32(46):16120-8. doi: 10.1523/JNEUROSCI.1572-12.2012. IP 8
43. Smidt MP, von Oerthel L, Hoekstra EJ, Schellevis RD, Hoekman MFM (2012) Spatial and Temporal Lineage Analysis of a Pitx3-Driven Cre-Recombinase Knock-In Mouse Model. *PLoS ONE* 7(8): e42641. doi:10.1371/journal.pone.0042641
44. Koushik Chakrabarty, Lars von oerthel, Anita Hellemons, M. frederic Clotman, Marian J.A. Groot Koerkamp, Frank C.P. Holstege, R. Jeroen Pasterkamp, and Marten P. Smidt (2012) Genome wide expression profiling of the mesodiencephalic region identifies novel factors involved in early and late dopaminergic development. *Biology Open* 1:693-704.
45. Laura A. Smit-Rigtera, Cornelle W. Noorlander, Lars von Oerthelb, Pascal Chameau, Marten P. Smidt\*, Johannes A. van Hooft\* (2012) Prenatal fluoxetine exposure induces life-long serotonin 5-HT<sub>3</sub> receptor-dependent cortical abnormalities and anxiety-like behaviour *Neuropharmacology* Volume 62, Issue 2: 865–870 \* Shared last author IP 4
46. Frank M.J. Jacobs\*, Jesse V. Veenvliet\*, Wadia H. Almirza, Elisa Hoekstra, Lars von Oerthel, Annemarie J.A. van der Linden, Roel Neijts, Marian Groot Koerkamp, Dik van Leenen, Frank C.P. Holstege, J. Peter H. Burbach and Marten P. Smidt, Retinoic acid-dependent and -independent gene-regulatory pathways of Pitx3 in mesodiencephalic dopaminergic neurons, *Development* 2011, 138(23):5213-22. \* shared first author. IP 8
47. Alves dos Santos MTM and Smidt MP. En1 and Wnt signaling in midbrain dopaminergic neuronal development. *Neural Development* 2011, 6:23 doi:10.1186/1749-8104-6-23 IP 3.4
48. Arango C., Gustincich S., Marin O., Parnavelas J. and Smidt M.\*, Chapter I: Brain development, plasticity and ageing in health and disease (Section Editor: Monica Di Luca) (Page 770) in; Di Luca M, Baker M, Corradetti R, Kettenmann H, Mendlewicz J, Olesen J, Ragan I, Westphal M. Consensus Document on European Brain Research, *Eur. J. Neurosci.* 2011 Mar;33(5):768-818 \* Theme leader.
49. Rosemann M, Ivashkevich A, Favor J, Dalke C, Hölter SM, Becker L, Rácz I, Bolle I, Klempt M, Rathkolb B, Kalaydjiev S, Adler T, Aguilar A, Hans W, Horsch M, Rozman J, Calzada-Wack J, Kunder S, Naton B, Gailus-Durner V, Fuchs H, Schulz H, Beckers J, Busch DH, Burbach JP, Smidt MP, Quintanilla-Martinez L, Esposito I, Klopstock T, Klingenspor M, Ollert M, Wolf E, Wurst W, Zimmer A, Hrabé de Angelis M, Atkinson M, Heinzmann U, Graw J. Microphthalmia, parkinsonism, and enhanced nociception in Pitx3 (416insG) mice. *Mamm Genome.* 2010 Feb;21(1-2):13-27.
50. Smidt MP. Specific vulnerability of substantia nigra compacta neurons. *J Neural Transm Suppl.* 2009;(73):39-47. (review upon invitation) IF 2.4



51. Kolk SM, Gunput RA, Tran TS, van den Heuvel DM, Prasad AA, Hellemons AJ, Adolfs Y, Ginty DD, Kolodkin AL, Burbach JP, Smidt MP, Pasterkamp RJ. Semaphorin 3F is a bifunctional guidance cue for dopaminergic axons and controls their fasciculation, channeling, rostral growth, and intracortical targeting. *J Neurosci*. 2009 Oct 7;29(40):12542-57. IP 8
52. Smidt MP\* and Burbach JPH. Terminal differentiation of mesodiencephalic dopaminergic neurons: the role of Nurr1 and Pitx3. *Adv. Exp. Med. Biol.* 2009;651:47-57.\*corresponding author. (IP 0.67)
53. Development and engineering of dopamine neurons. Preface. Pasterkamp RJ, Smidt MP, Burbach JP. *Adv Exp Med Biol.* 2009, 651.
54. Smidt MP\* and Burbach JPH A passport to neurotransmitter identity. *Genome Biology* 2009, 10:229. \*corresponding author. IP 9. (review upon invitation)
55. Jacobs FMJ, van der Linden AJA, Wang Y, von Oerthel L, Sul HS, Burbach JPH and Smidt MP. Identification of Dlk1, Ptpu and Khlh1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons. *Development* 2009 Jul;136(14):2363-73 (selected to feature on the In this Issue page of Issue 136.14). IF 8
56. Jacobs FMJ, van Erp S, van der Linden AJA, von Oerthel L, Burbach JPH and Smidt MP. Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. *Development* 2009 Feb;136(4):531-40 (selected to feature on the In this Issue page of Issue 136.04) IF 8.
57. Noorlander, CW, Ververs, FFT, Nikkels, PGJ, van Echteld, CJA, Visser, GHA, Smidt, MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. *PLoS ONE* June 23, 2008.
58. Smits SM, Noorlander CW, Kas MJ, Ramakers GM, Smidt MP. Alterations in serotonin signalling are involved in the hyperactivity of Pitx3-deficient mice. *Eur J Neurosci*. 2008 Jan;27(2):388-95. PMID: 18215235 IP 4.2
59. Vastenhouw B, van der Have F, van der Linden AJ, von Oerthel L, Booij J, Burbach JP, Smidt MP, Beekman FJ. Movies of dopamine transporter occupancy with ultra-high resolution focusing pinhole SPECT. *Mol Psychiatry*. 2007 Nov;12(11):984-7. Epub 2007 Jul 10. PMID: 17957236 IF 12
60. Kas MJ, van der Linden AJ, Oppelaar H, von Oerthel L, Ramakers GM, Smidt MP. Phenotypic segregation of aphakia and Pitx3-null mutants reveals that Pitx3 deficiency increases consolidation of specific movement components. *Behav Brain Res*. 2008 Jan 25;186(2):208-14. Epub 2007 Aug 31. PMID: 17919745 IF 2.4
61. Jacobs FM, Smits SM, Noorlander CW, von Oerthel L, van der Linden AJ, Burbach JP, Smidt MP. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. *Development*. 2007 Jul;134(14):2673-84. PMID: 17592014 IF 8
62. Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer K, Smidt MP, Klein R. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. *PLoS Biol*. 2007 Mar;5(3):e39. PMID: 17298183 IF 15
63. Smidt MP\*, Burbach JP. How to make a mesodiencephalic dopaminergic neuron. *Nat Rev Neurosci*. 2007 Jan;8(1):21-32. Review. PMID: 17180160 \* corresponding author IF 27
64. Burbach JP, Smidt MP. Molecular programming of stem cells into mesodiencephalic dopaminergic neurons. *Trends Neurosci*. 2006 Nov;29(11):601-3. Epub 2006 Oct 9. Review. PMID: 17030431 IF 14
65. Smits SM, Smidt MP. The role of Pitx3 in survival of midbrain dopaminergic neurons. *J Neural Transm Suppl*. 2006;(70):57-60. Review. IF 2.4
66. Sgadò P, Albéri L, Gherbassi D, Galasso SL, Ramakers GM, Alavian KN, Smidt MP, Dyck RH, Simon HH. Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. *Proc Natl Acad Sci U S A*. 2006 Oct 10;103(41):15242-7. Epub 2006 Oct 2. PMID: 17015829 IF 10
67. van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. *Prog Neurobiol*. 2006 Jul;79(4):205-21. Epub 2006 Aug 17. Review. PMID: 16916571 IF 12
68. de Rover M, Lodder JC, Smidt MP, Brussaard AB. Pitx3 deficiency in mice affects cholinergic modulation of GABAergic synapses in the nucleus accumbens. *J Neurophysiol*. 2006 Oct;96(4):2034-41. Epub 2006 Jul 12. PMID: 16837663 IF 3.9
69. Jacobs FM, Smits SM, Hornman KJ, Burbach JP, Smidt MP. Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons. *J Physiol*. 2006 Sep 1;575(Pt 2):397-402. Epub 2006 Jun 29. Review. PMID: 16809365 IF 4.4

70. Wijchers PJ, Burbach JP, Smidt MP. In control of biology: of mice, men and Foxes. *Biochem J*. 2006 Jul 15;397(2):233-46. Review. PMID: 16792526 IF 29
71. Asbreuk CH, van Doorninck JH, Mansouri A, Smidt MP, Burbach JP. Neurohypophysial dysmorphogenesis in mice lacking the homeobox gene *Uncx4.1*. *J Mol Endocrinol*. 2006 Feb;36(1):65-71. PMID: 16461927 IF 5.8
72. Smits SM, Burbach JP, Smidt MP. Developmental origin and fate of meso-diencephalic dopamine neurons. *Prog Neurobiol*. 2006 Jan;78(1):1-16. Epub 2006 Jan 18. Review. PMID: 16414173 IF 12
73. Wijchers PJ, Hoekman MF, Burbach JP, Smidt MP. Identification of forkhead transcription factors in cortical and dopaminergic areas of the adult murine brain. *Brain Res*. 2006 Jan 12;1068(1):23-33. Epub 2005 Dec 27. PMID: 16376864 IF 1.7
74. Hoekman MF, Jacobs FM, Smidt MP, Burbach JP. Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. *Gene Expr Patterns*. 2006 Jan;6(2):134-40. Epub 2005 Dec 2. PMID: 16326148 IF 2.3
75. Wijchers PJ, Hoekman MF, Burbach JP, Smidt MP. Cloning and analysis of the murine Foxi2 transcription factor. *Biochim Biophys Acta*. 2005 Nov 10;1731(2):133-8. Epub 2005 Oct 5. PMID: 16289364 IF 2.1
76. Smits SM, van der Nobelen S, Hornman KJ, von Oerthel L, Burbach JP, Smidt MP. Signalling through phospholipase C beta 4 is not essential for midbrain dopaminergic neuron survival. *Neuroscience*. 2005;136(1):171-9. Epub 2005 Sep 28. PMID: 16198487 IF 3.5
77. Smits SM, Mathon DS, Burbach JP, Ramakers GM, Smidt MP. Molecular and cellular alterations in the *Pitx3*-deficient midbrain dopaminergic system. *Mol Cell Neurosci*. 2005 Nov;30(3):352-63. Epub 2005 Sep 6. PMID: 16140547 IF 3.8
78. Kleefstra T, Smidt MP, Banning MJ, Oudakker AR, Van Esch H, de Brouwer AP, Nillesen W, Sistermans EA, Hamel BC, de Bruijn D, Fryns JP, Yntema HG, Brunner HG, de Vries BB, van Bokhoven H. Disruption of the gene *Euchromatin Histone Methyl Transferase1 (Eu-HMTase1)* is associated with the 9q34 subtelomeric deletion syndrome. *J Med Genet*. 2005 Apr;42(4):299-306. PMID: 15805155 IF 6.3
79. Burbach JP, Smidt MP Response to Simeone: Coexpression of *Pitx3* with tyrosine hydroxylase in midbrain dopaminergic neurons, *Trends Neurosci*. 2005 28(2), 65-66. IF 14.5
80. Beekman FJ, van der Have F, Vastenhouw B, van der Linden AJ, van Rijk PP, Burbach JP, Smidt MP. U-SPECT-I: a novel system for submillimeter-resolution tomography with radiolabeled molecules in mice. *J Nucl Med*. 2005 Jul;46(7):1194-200. PMID: 16000289 IF 4.9 Best science paper in J. Nucl. Med 2005 award
81. van der Heide LP, Jacobs FM, Burbach JP, Hoekman MF, Smidt MP. FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleo-cytoplasmic shuttling. *Biochem J*. 2005 Nov 1;391(Pt 3):623-9. PMID: 15987244 IF 4.3
82. van der Heide LP, Smidt MP. Regulation of FoxO activity by CBP/p300-mediated acetylation. *Trends Biochem Sci*. 2005 Feb;30(2):81-6. PMID: 15691653 IF 14.3
83. Mathon DS, Lesscher HM, Gerrits MA, Kamal A, Pintar JE, Schuller AG, Spruijt BM, Burbach JP, Smidt MP, van Ree JM, Ramakers GM. Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice. *Neuroscience*. 2005;130(2):359-67. PMID: 15664692 IF 3.5
84. Thuret S, Alavian KN, Gassmann M, Lloyd CK, Smits SM, Smidt MP, Klein R, Dyck RH, Simon HH. The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta. *J Neurochem*. 2004 Dec;91(6):1302-11. PMID: 15584907 IF 5
85. Smidt MP\*, Smits SM, Burbach JP. Homeobox gene *Pitx3* and its role in the development of dopamine neurons of the substantia nigra. *Cell Tissue Res*. 2004 Oct;318(1):35-43. Epub 2004 Aug 6. Review. PMID: 15300495 \*corresponding author IF 2.6
86. Smits SM, Terwisscha van Scheltinga AF, van der Linden AJ, Burbach JP, Smidt MP. Species differences in brain pre-pro-neurotensin/neuromedin N mRNA distribution: the expression pattern in mice resembles more closely that of primates than rats. *Brain Res Mol Brain Res*. 2004 Jun 18;125(1-2):22-8. PMID: 15193419 IF 2.4
87. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. *Biochem J*. 2004 Jun 1;380(Pt 2):297-309. Review. PMID: 15005655 IF 29.4

88. Smidt MP, Smits SM, Bouwmeester H, Hamers FP, van der Linden AJ, Hellemons AJ, Graw J, Burbach JP. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Ptx3. *Development*. 2004 Mar;131(5):1145-55. PMID: 14973278 IF 8
89. Mathon DS, Kamal A, Smidt MP, Ramakers GM. Modulation of cellular activity and synaptic transmission in the ventral tegmental area. *Eur J Pharmacol*. 2003 Nov 7;480(1-3):97-115. Review. PMID: 14623354 IF 2.3
90. Smidt MP, Smits SM, Burbach JP. Molecular mechanisms underlying midbrain dopamine neuron development and function. *Eur J Pharmacol*. 2003 Nov 7;480(1-3):75-88. Review. PMID: 14623352 IF 2.3
91. Smits SM, Ponnio T, Conneely OM, Burbach JP, Smidt MP. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. *Eur J Neurosci*. 2003 Oct;18(7):1731-8. PMID: 14622207 IF 4.2
92. Kromkamp M, Uylings HB, Smidt MP, Hellemons AJ, Burbach JP, Kahn RS. Decreased thalamic expression of the homeobox gene DLX1 in psychosis. *Arch Gen Psychiatry*. 2003 Sep;60(9):869-74. PMID: 12963668 IF 12
93. Vogelaar CF, Smits SM, Brakkee JH, Gispén WH, Smidt MP, Schrama LH, Hoekman MFM, Burbach JP Homeobox gene repertoire in adult rat dorsal root ganglia. *Neurosci. Res. Commun*. 2003;32, 49-59. IF 0.3
94. Jacobs FM, van der Heide LP, Wijchers PJ, Burbach JP, Hoekman MF, Smidt MP. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. *J Biol Chem*. 2003 Sep 19;278(38):35959-67. Epub 2003 Jul 11. PMID: 12857750 IF 8
95. Burbach JP, Smits S, Smidt MP. Transcription factors in the development of midbrain dopamine neurons. *Ann N Y Acad Sci*. 2003 Jun;991:61-8. Review. PMID: 12846974 IF 1.5
96. Asbreuk CH, Vogelaar CF, Hellemons A, Smidt MP, Burbach JP. CNS expression pattern of Lmx1b and coexpression with ptx genes suggest functional cooperativity in the development of forebrain motor control systems. *Mol Cell Neurosci*. 2002 Nov;21(3):410-20. PMID: 12498783 IF 4.5
97. Asbreuk CH, van Schaick HS, Cox JJ, Smidt MP, Burbach JP. Survey for paired-like homeodomain gene expression in the hypothalamus: restricted expression patterns of Rx, Alx4 and gooseoid. *Neuroscience*. 2002;114(4):883-9. PMID: 12379244 IF 3.5
98. Asbreuk CH, van Schaick HS, Cox JJ, Kromkamp M, Smidt MP, Burbach JP. The homeobox genes Lhx7 and Gbx1 are expressed in the basal forebrain cholinergic system. *Neuroscience*. 2002;109(2):287-98. PMID: 11801365 IF 3.5
99. Smidt MP, Cox JJ, van Schaick HS, Coolen M, Schepers J, van der Kleij AM, Burbach JP. Analysis of three Ptx2 splice variants on transcriptional activity and differential expression pattern in the brain. *J Neurochem*. 2000 Nov;75(5):1818-25. PMID: 11032870 IF 5
100. Cazorla P, Smidt MP, O'Malley KL, Burbach JP. A response element for the homeodomain transcription factor Ptx3 in the tyrosine hydroxylase gene promoter. *J Neurochem*. 2000 May;74(5):1829-37. PMID: 10800925 IF 5
101. Smidt MP, Asbreuk CH, Cox JJ, Chen H, Johnson RL, Burbach JP. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. *Nat Neurosci*. 2000 Apr;3(4):337-41. PMID: 10725922 IF 15
102. Burbach JP, van Schaick H, Lopes da Silva S, Asbreuk CH, Smidt MP. Hypothalamic transcription factors and the regulation of the hypothalamo-neurohypophysial system. *Adv Exp Med Biol*. 1998;449:29-37. Review. PMID: 10026783
103. Smidt MP, Snippe L, van Keulen G, Ab G. The bZip transcription factor vitellogenin-binding protein is post transcriptional down regulated in chicken liver. *Eur J Biochem*. 1998 Aug 15;256(1):106-11. PMID: 9746352 IF 3
104. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, Smidt MP, Cox JJ, De Mayo F, Burbach JP, Conneely OM. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. *Proc Natl Acad Sci U S A*. 1998 Mar 31;95(7):4013-8. PMID: 9520484 IF 9
105. Smidt MP, van Schaick HS, Lanctôt C, Tremblay JJ, Cox JJ, van der Kleij AA, Wolterink G, Drouin J, Burbach JP. A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. *Proc Natl Acad Sci U S A*. 1997 Nov 25;94(24):13305-10. PMID: 9371841 IF 9

106. van Schaick HS\*, Smidt MP\*, Rovescalli AC, Luijten M, van der Kleij AA, Asoh S, Kozak CA, Nirenberg M, Burbach JP. Homeobox gene Prx3 expression in rodent brain and extraneural tissues. *Proc Natl Acad Sci U S A*. 1997 Nov 25;94(24):12993-8. PMID: 9371788 \*shared first author IF 9
107. Smidt MP, Russchen B, Snippe L, Wijnholds J, Ab G. Cloning and characterisation of a nuclear, site specific ssDNA binding protein. *Nucleic Acids Res*. 1995 Jul 11;23(13):2389-95. PMID: 7630716 IF 7
108. Smidt MP, Wijnholds J, Snippe L, van Keulen G, Ab G. Binding of a bZip protein to the estrogen-inducible apoVLDL II promoter. *Biochim Biophys Acta*. 1994 Sep 13;1219(1):115-20. PMID: 8086448 IF 4
109. van der Ploeg J, Smidt MP, Landa AS, Janssen DB. Identification of Chloroacetaldehyde Dehydrogenase Involved in 1,2-Dichloroethane Degradation. *Appl Environ Microbiol*. 1994 May;60(5):1599-1605. PMID: 16349259 IF 4
110. Beintema JJ, Stam WT, Hazes B, Smidt MP. Evolution of arthropod hemocyanins and insect storage proteins (hexamerins). *Mol Biol Evol*. 1994 May;11(3):493-503. PMID: 8015442 IF 5.3
111. Van Rijssel M, Smidt MP, Van Kouwen G, Hansen TA. Involvement of an Intracellular Oligogalacturonate Hydro-lase in Metabolism of Pectin by *Clostridium thermosaccharolyticum*. *Appl Environ Microbiol*. 1993 Mar;59(3):837-842. PMID: 16348892 IF 4

### 9.3 Patent applications:

- Smidt MP, Burbach JPH European Patent application, Genes with restricted expression/Genes with restricted expression in mesencephalic dopaminergic neurons, Filed 1997.
- P113870EP00 and PCT application: WO 2018/160067 A1. Inventor J.P. van de Heide, Full licensed to Macrobian Biotech BV
- European patent application No. 18192799.7 and PCT, Universiteit van Amsterdam; Inventors: dr. J.P. van de Heide and prof. dr. M.P. Smidt., Full licensed to Macrobian Biotech BV

### 9.4 Companies

- Macrobian Biotech BV, [www.macrobianbiotech.com](http://www.macrobianbiotech.com):

Macrobian-Biotech was founded in May 2017 by Dr. Lars van der Heide and Prof. dr. Marten Smidt. Its primary goal is to perform pre-clinical research that leads to novel treatments for disorders that affect the midbrain dopamine system. The company is currently housed at the Amsterdam Science Park, the heart of academic excellence in the Netherlands.

### 9.5 Books (chapters)

1. Smidt MP, Burbach, JP (2000) Transcription factors in the development of the mesencephalic dopamine system. In: *Molecular genetics of mental disorders* Ed: M. Briley&F. Sulser. 269-287.
2. Burbach JP, van Schaick HSA, Lopes da Silva S, Asbreuk CHJ, Smidt MP (1998) Hypothalamic transcription factors and the regulation of the hypothalamo-neurohypophysial system. In: *Vasopressin and Oxytocin. Molecular, Cellular and Clinical Advances* (Eds. H.H. Zingg, C.W. Bourque and D.G. Bichet), *Advances in Experimental Medicine and Biology* 449, Plenum Press, New York, pp. 29-37.
3. *Development and Engineering of Dopamine Neurons*, Series: *Advances in Experimental Medicine and Biology*, Vol. 651 Pasterkamp, Jeroen R.; Smidt, Marten P.; Burbach, J. Peter H. (Eds.), 2009, 143 p. 26 illus., 5 in color., Hardcover, ISBN: 978-1-4419-0321-1
4. Smidt, MP\*, Burbach JP (2009) Terminal differentiation of mesodiencephalic dopaminergic neurons: the role of Nurr1 and Pitx3. In "Dopamine development and engineering" (Eds. J. Pasterkamp, M.P. Smidt, J.P.H. Burbach) <http://www.eurekah.com/chapter/3937> \*corresponding author
5. Smidt MP, Specific vulnerability of substantia nigra compacta neurons. In: *BIRTH, LIFE AND DEATH OF DOPAMINERGIC NEURONS IN THE SUBSTANTIA NIGRA* Eds: Di Giovanni G, Di Matteo V, Esposito E. *Journal Neuraltransmission Supplementum*, 2009. in press Springer- Verlag, Wien-New York.
6. Smidt, MP, Development of brain monoaminergic systems. In: *Neurobiology of Depression* Eds: F. Lopez and C. Alamo. *Frontiers of Neuroscience*, CRC press, 2011.

### 9.6 Other scientific contributions

1. Smidt MP. Depression and Dopamine. *Front. Neurosci*. 2009; 3(2): 279. (research highlight).

## 10 Citation information

- Total cites: 9361 (2608 since 2016)
- H-index: 44 (28 since 2016)
- i10-index 81 (62 since 2016)